Arch vs Enzyme Finance: Which fits your investing needs? (2026)

Arch and Enzyme both sit in the index and tokenized-fund category, but they serve different users. Arch presents curated crypto exposure as products an investor can select, including diversified and risk-profile funds and Bitcoin+. Its focus is mostly Spanish-speaking investors in Latin America, and it supports bank withdrawals in Chile, Colombia, Mexico, Argentina and Peru.

Enzyme is infrastructure for people and organizations that create or manage investment products. Onyx is its fund-issuance stack, Blue supports decentralized strategies, and Myso offers on-chain options. Its compliance tools, APIs and white-label features reinforce that business and institutional focus. The scale figures also differ sharply: Arch reports about $87,000 in TVL, while Enzyme has about $94 million. That is a substantial gap in reported on-chain value, though TVL alone does not establish performance or safety.

Neither platform publishes a complete fee schedule in the information here, so you cannot make a reliable cost comparison from stated rates alone. Arch’s $50 Digital plan is an account tier, not a fee. Its higher Preferente and Alto Patrimonio tiers begin at $10,000 and $100,000, respectively, and add adviser or custom-service options. Arch also notes minimums for bank deposits and withdrawals, set in local currency by payment providers; those are transaction thresholds, not management fees.

Enzyme does not publish specific pricing details here either. It directs Onyx users to a pricing page, while individual vault managers may set management or performance fees. Network gas fees also apply when interacting on-chain. Before depositing or issuing a product, check the product or vault terms for management charges, performance fees, spreads, payment-provider costs and network fees.

Both platforms have two audits listed, but neither names the auditors or explains the scope in the information here. Arch says client assets are kept separate from its own and that transactions are recorded on-chain. It also says it is still in the process of registering with Chile’s CMF under the Fintech law, so registration should not be assumed. Withdrawals require identity verification, and users face digital-asset, smart-contract and counterparty risks.

Enzyme says it is SOC 2 certified and describes security, availability and confidentiality controls. That claim is not a guarantee against loss. Enzyme vault users also take on risks from smart contracts, managers’ strategies and any third-party protocols those strategies use. Its compliance tooling can support an issuer’s processes, but does not make a fund compliant or approved by itself. For either platform, understand the specific product and the rules that apply where you live before investing.

Arch is designed to make portfolio selection more straightforward: users choose a fund, payment currency and amount, and can sign up by email or Gmail or connect a wallet. Its products package several assets into one investment, so users do not have to select each coin individually. The site is mainly in Spanish, and the local bank options are aimed at Latin American customers. Arch warns that an investment can lose its entire value.

Enzyme has a broader and more technical product range. Onyx supports tokenized funds and instruments, while Blue provides tools for managers to run strategies across protocols and assets. Myso adds options products, and APIs and SDKs let issuers integrate products into their own interfaces. That flexibility may suit experienced teams better than casual investors. Enzyme’s older Blue interface is marked legacy, which may add complexity for people navigating its product lineup.

Choose Arch if you want a packaged crypto fund, value a low stated entry point, and are in a Latin American market where its local bank withdrawals are available. Its onboarding and product menu are more investor-facing, but fees remain unclear and its TVL is small. Its Chilean regulatory registration is still in progress, so do not treat it as completed.

Choose Enzyme if you are an asset manager, institution or issuer that needs to create, administer or embed tokenized investment products. Its higher TVL, support for Arbitrum as well as Ethereum and Polygon, and institutional tooling make it the stronger fit for that purpose. It is less clearly suited to someone seeking a simple ready-made portfolio. In either case, compare the specific product’s fees and risks before investing; neither platform’s audits or compliance features remove the possibility of loss.